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Abstract
The medial septal region (medial septum and diagonal band of Broca, MS/DB) controls
hippocampal excitability and synaptic plasticity. MS/DB cholinergic neurons degenerate early in
Alzheimer’s disease (AD). The presence of MS/DB glutamatergic neurons that project to the
hippocampus and are vulnerable to Aβ suggests that excitotoxicity plays a role in AD septal
degeneration and hippocampal dysfunction. To demonstrate the presence of excitotoxicity in Aβ-
induced septal damage, we compared rats injected with Aβ1–40 into the MS/DB with animals
treated with memantine prior, during and after Aβ1–40 injections. Controls were injected with
phosphate buffered saline (PBS). MS/DB cholinergic, glutamatergic and GABAergic neurons
were immunochemically identified. The number of MS/DB neurons was estimated using
stereology. Our results show that memantine blocks Aβ1–40-induced septal damage and suggest
that excitotoxicity plays a role in basal forebrain neurodegeneration.
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Introduction
Alzheimer’s disease (AD) is a progressive and devastating neurological disorder that leads
to dementia and subsequent death. The basal forebrain, including the septum, is affected by
AD with a severe reduction of cholinergic neurons [2, 8, 23]. The MS/DB region of the
septum projects to the hippocampus. By controlling the excitability and synaptic plasticity of
hippocampus, the MS/DB plays an important role in learning and memory [4]. The MS/DB
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was previously thought to exclusively contain cholinergic and GABAergic neurons.
However, our laboratory has characterized a third population of MS/DB neurons that uses
glutamate as neurotransmitter and projects to the hippocampus [3]. Thus, glutamatergic
neurons are well posed to play an important role in septo-hippocampal functions and their
damage may contribute to AD brain dysfunction.
Medial septal cholinergic and glutamatergic neurons are vulnerable to both medial septal
and hippocampal injections of amyloid β peptides (Aβ) [5, 6]. Thus, excitotoxicity triggered
by Aβ-induced septal glutamatergic neuronal damage may contribute to both cholinergic
and glutamatergic neuronal degeneration. Memantine an uncompetitive N-methyl- D-
aspartate (NMDA) receptor antagonist improves both cognitive and behavioral symptoms of
AD [7, 10, 14, 16, 21]. Our work is dedicated to determine whether excitotoxicity
contributes to the Aβ-induced septal lesions. While Aβ1–42 is the most fibrillogenic [26] Aβ
form and a major component of the neuritic plaques, Aβ1–40 is the most common Aβ variety
in the brain [20]. Since plaques are not present in the basal forebrain until advanced AD
stages, and degeneration of basal forebrain cholinergic neurons occurs earlier in this
disorder, we decided to use Aβ1–40 for this study. Our results show that memantine
effectively protects against the damage produced by intraseptal administration of Aβ1–40.
Materials and Methods
Twelve male Sprague Dawley Rats weighing 300–400g were divided into three groups. Two
experimental groups were injected with 4μl Aβ1–40 (Bachem) dissolved in distilled water
[11, 22] concentration of 2μg/μl into the medial septal [5, 12] (coordinates: AP=−0.5, L=2,
V= 6.5). One of the experimental groups was treated with a bolus of memantine
hydrochloride (Sigma, St. Louis, MO) 20mg/kg in a volume of 1ml of saline solution
subcutaneously injected 12 hours prior intraseptal injections of Aβ and the implantation of
osmotic pumps (Alzet, 2ML2). Memantine was continuously delivered subcutaneously
through the osmotic pumps for eight days (20mg/Kg/day) [8]. Control animals were injected
with equal amounts of a PBS solution (4μl). One week after injection of Aβ1–40 or PBS,
animals were perfused intracardially with a fixative solution. Brains were removed,
cryoprotected and 50μm slices prepared. Cholinergic neurons were labelled with goat anti-
ChAT antibody (1:200, Chemicon), glutamatergic neurons with a mouse anti-glutamate
antibody (1:2000, Immunostar) and GABAergic neurons with a mouse anti-GAD67
antibody (1:500, Chemicon). Slices were then incubated with their respective biotinylated
secondary antibodies (1:200, Vector). Finally, slices were incubated with avidin-biotin
complex (ABC) and neurons visualized using the chromogen 3-3′ diaminobenzidine. Two
sections of each brain were incubated without the primary antibody to determine staining
specificity. No immunostaining was observed in these cases.
Thioflavine S method was used to confirm the Aβ injection site and detection of fibrillary
forms (Figure 1). A sample of the Aβ1–40 was analyzed with Atomic Force Microscope
(AFM) (Digital Instruments, Veeco, Santa Barbara, CA) to determine the Aβ1–40
conformation. Aβ peptide adopted mostly a fibrillar form. The width of single fibrils was
about 5nm with variable length. Some oligomers coexist with the fibrillar form (Figure 1).
Neuronal numbers were estimated using stereological approaches (StereoInvestigator
software, MicroBrightField, Williston, VT, USA) [24]. All numerical data were expressed
as t value (t), means and standard error of the mean (SEM). Student-t-tests were used to
assess statistically significant differences among neuronal populations. Differences were
considered significant at p<0.05.
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The number of MS/DB ChAT immunoreactive neurons was reduced from 10021± 664 in
PBS injected animals to 6469±122 in Aβ1–40 injected rats (t=6.134, df3),(p=0.009). The
number of ChAT immunoreactive neurons in memantine/Aβ treated animals was similar to
the one found for the control animals 9209±339 (p=0.25) (and significantly different from
Aβ1–40 treated animals 6469±122 (t=−11.879, df3), (p=0.001) (Figure 1 and 2). Thus,
memantine treatment was able to protect against Aβ1–40-induced toxicity (Figures 1 and 2).
Similarly, Aβ1–40 reduced the number of glutamate immunoreactive neurons from
19421±1216 to 14118±579 (t=4.671, df3),(p=.019). Here also, memantine treatment was
able to protect against Aβ1–40-induced toxicity and the number of glutamate
immunoreactive neurons in memantine/Aβ1–40 treated (Figure 1 and 2) animals was
(20052±1118) and significantly different from Aβ1–40 treated rats/no treatment 14118±579
(t=−3.522, df3),(p=.039). The number of glutamate immunoreactive neurons in memantine/
Aβ treated animals was similar to the one found for the control animals 19421±1216
(p=0.75) (Figures 1 and 2). In contrast, Aβ1–40 did not significantly reduce the number of
GABAergic neurons and memantine treatment did not modify their numbers (Figures 1 and
2).
Discussion
The toxicity caused by excessive neuronal stimulation (excitotoxicity), with subsequent
calcium entry into the neuron, may occur in any brain region containing NMDA receptors
(or other calcium permeable glutamate receptors) [1] and axon terminals with capacity to
release glutamate. Aβ administration disrupts neuron-glia signaling and glial glutamate
uptake, increasing glutamate concentrations in the extracellular space that surround neurons.
Via this mechanism, Aβ induces noxious glutamatergic stimulation of neurons. In fact,
excessive activation of NMDA receptors has been postulated to play a critical role in AD
neurodegeneration [9, 13]. Furthermore, Aβ increases the firing rates of MS/DB
glutamatergic neurons by blocking specific K+ conductances [15]. This network activity
intensification may also activate excitotoxic mechanisms.
Memantine has been shown to protect neurons against Aβ-induced toxicity in several brain
regions [10, 14, 17, 18]. This protective effect is thought to occur by selective blockade of
the excitotoxicity associated with abnormal glutamatergic transmission, while allowing for
the physiological transmission associated with normal neuronal functioning [19]. The
presence of a major population of glutamatergic neurons in the MS/DB that participates in
local circuits [3, 4, 25], suggests that excitotoxic mechanisms participate in the Aβ-induced
damage of this basal forebrain region. Nevertheless, up to the present study, memantine
effects on limited Aβ-induced septal lesions have not been investigated. Our work
demonstrates that memantine protects against Aβ1–40- induced MS/DB neuronal damage [5,
6] and that local excitotoxic mechanisms may significantly contribute to AD basal
neurodegeneration. Neuronal network activity and intracellular calcium changes need to be
investigated to determine the molecular mechanisms underlying the memantine protective
effect.
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• Neurons of the medial septum are affected by β Amyloid 1–40.
• Excitotoxicity contributes to septal degeneration in neurons.
• Memantine protects against β Amyloid 1–40.
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(A-1) A deflection AFM image of Aβ1–40 showing predominantly fibrillar form with some
oligomers (white arrows). (A-2) A height AFM image of the Aβ1–40 fibrils. The fibrillar
form covers about 97% of the total surface (Scale bar: 550 nm). (B-1) Diagram depicting
medial septum injection site. (B-2) Fluorescent image of Thioflavine S in medial septum
verifying presence of Aβ 1–40 (Scale bar=100μm). (C)Graph comparing the estimated
number of glutamatergic, cholinergic, and GABAergic labeled neurons in the MS/DB from
control, Aβ1–40 and Memantine + Aβ1–40, rats. The graph shows Aβ1–40 significantly
reduced the medial septal glutamatergic and cholinergic neurons (P<0.05.) compared to PBS
and memantine treated rats. In contrast, GABAergic neurons did not show significant
alterations.
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Bright field photomicrographs of ChAT (A–F) Glutamate (G–L) and GAD67 (M–R)
immunoreactive neurons in medial septum. Left columns (5X), right columns (40x) in
Aβ1–40+memantine group, Aβ1–40, and PBS treated groups. In (D, J) notice a reduction in
ChAT and Glutamate immunoreactive neurons in the Aβ1–40 group. (P)GAD67
immunoreactivity shows no evident changes in Aβ1–40injected group or memantine treated
group. (Scale bar=50 μm in R).
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